Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1625 1626
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 15734199 | ESTROGEN RECEPTOR INHIBITORS AND USES THEROF | Final Rejection | The Regents of the University of California |
| 17998391 | THERAPEUTIC COMBINATIONS COMPRISING A CRAF INHIBITOR | Final Rejection | NOVARTIS AG |
| 18525536 | METHYLQUINAZOLINONE DERIVATIVES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18564968 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | Non-Final OA | Merck Patent GmbH |
| 18473202 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | Non-Final OA | DUKE UNIVERSITY |
| 18570398 | (1,4,5-TRISUBSTITUTED-1H-PYRAZOL-3-YL)OXY-2-ALKOXY ALKYL ACIDS AND THEIR DERIVATIVES, THEIR SALTS AND THEIR USE AS HERBICIDAL AGENTS | Non-Final OA | Bayer AKtiengesellschaft |
| 18056682 | METHODS AND COMPOSITIONS FOR TREATING ATHEROSCLEROSIS | Non-Final OA | Sanford Burnham Prebys Medical Discovery Institute |
| 18574027 | COMPOSITIONS FOR TREATMENT OF DIABETIC SYMPTOMS | Non-Final OA | Innocan Pharma Ltd. |
| 18564894 | BZD-1 AS A CHEMOSENSITIZER OF CANCER | Non-Final OA | UWM Research Foundation, Inc. |
| 16627146 | CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND | Final Rejection | TAIHO PHARMACEUTICAL CO., LTD. |
| 18474027 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | Non-Final OA | VORONOI INC. |
| 18043298 | PHARMACEUTICAL COMBINATION AND TUMOR TREATMENT | Final Rejection | IDEAYA Biosciences Inc. |
| 17297580 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING OMEGA-3 FATTY ACID ETHYL ESTERS | Non-Final OA | NOVALIQ GMBH |
| 18285800 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | Non-Final OA | TOLREMO THERAPEUTICS AG |
| 18473540 | Methods Of Treating Cancer With Transmembrane Protein 16F (TMEM16F) Inhibitors | Non-Final OA | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center |
| 18241260 | CO-PROCESSED PRE-FORMULATED EXCIPIENT COMPOSITION FOR POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | Non-Final OA | Sigachi Industries Limited |
| 18213451 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | Non-Final OA | Enalare Therapeutics Inc. |
| 18012122 | Compositions and Kits of Parts Comprising N,N-Dimethyltryptamine and Harmine and Their Use in Therapy | Non-Final OA | University of Zürich |
| 17632323 | COMPOUND FOR COMBINATION TREATMENT | Final Rejection | Initiator Pharma A/S |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy